Correlation between GH and IGF-1 during treatment for acromegaly

2016 ◽  
Vol 126 (6) ◽  
pp. 1959-1966 ◽  
Author(s):  
Edward H. Oldfield ◽  
John A. Jane ◽  
Michael O. Thorner ◽  
Carrie L. Pledger ◽  
Jason P. Sheehan ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Response To Treatment ◽  
Gh Secretion ◽  
Wide Range ◽  
Before And After ◽  
Z Scores ◽  
Tumor Viability ◽  
The Relationship ◽  
Over Time

OBJECTIVEThe relationship between growth hormone (GH) and insulin-like growth factor–1 (IGF-1) in patients with acromegaly as serial levels drop over time after treatment has not been examined previously. Knowledge of this relationship is important to correlate pretreatment levels that best predict response to treatment. To examine the correlation between GH and IGF-1 and IGF-1 z-scores over a wide range of GH levels, the authors examined serial GH and IGF-1 levels at intervals before and after surgery and radiosurgery for acromegaly.METHODSThis retrospective analysis correlates 414 pairs of GH and IGF-1 values in 93 patients with acromegaly.RESULTSAbsolute IGF-1 levels increase linearly with GH levels only up to a GH of 4 ng/ml, and with IGF-1 z-scores only to a GH level of 1 ng/ml. Between GH levels of 1 and 10 ng/ml, increases in IGF-1 z-scores relative to changes in GH diminish and then plateau at GH concentrations of about 10 ng/ml. From patient to patient there is a wide range of threshold GH levels beyond which IGF-1 increases are no longer linear, GH levels at which the IGF-1 response plateaus, IGF-1 levels at similar GH values after the IGF-1 response plateaus, and of IGF-1 levels at similar GH levels.CONCLUSIONSIn acromegaly, although IGF-1 levels represent a combination of the integrated effects of GH secretion and GH action, the tumor produces GH, not IGF-1. Nonlinearity between GH and IGF-1 occurs at GH levels far below those previously recognized. To monitor tumor activity and tumor viability requires measurement of GH levels.

scholarly journals Neuroarchitecture Assessment: An Overview and Bibliometric Analysis

2021 ◽  
Vol 11 (4) ◽  
pp. 1362-1387
Author(s):  
Hessam Ghamari ◽  
Nasrin Golshany ◽  
Parastou NaghibiRad ◽  
Farzaneh Behzadi
Keyword(s):  
Bibliometric Analysis ◽  
Science Mapping ◽  
Analysis Techniques ◽  
Mapping Tool ◽  
Wide Range ◽  
Range Spread ◽  
Methodological Approaches ◽  
The Relationship ◽  
Major Progress ◽  
Over Time

Research on the relationship between architecture and neuroscience has increased in number and significance since the 1990s. Although a growing number of studies revolve around this field of research, there are very limited studies that have reviewed and assessed the field and there is a gap in the literature to address the overall analysis of neuroarchitecture literature and its evolution. Additionally, neuroarchitecture literature is now challenging to manage because of its multidisciplinary scope and wide range spread within different themes and journals. The primary aim of this study is to present a bibliometric analysis of three decades of research on neuroarchitecture. This provides an overall picture of the field and its research landscape. Two hundred and ninety-five publications were included in the final database of the study after screening processes. Next, a science mapping tool, VOSviewer, was utilized to detect major topics as well as influential authors, countries, publications, and prominent journals using different network analysis techniques such as term co-citation, term co-occurrence, and bibliographic coupling. Next, a similar co-occurrence analysis was conducted to identify the major themes and the evolution of the intellectual basis of the field. SciMAT was also used to detect how the intellectual base of the knowledge in the field has evolved over time. It also assisted to identify the major themes that have contributed to this evolution. The results show that this field has initially been mainly focused on few themes but has later become more diversified to acknowledge the multi-faceted characteristics of neuroarchitecture; over time, the intellectual base of the field of neuroarchitecture started to grow, particularly from 2016. Major progress in the development of theoretical and methodological approaches has been achieved and there has been a paradigm shift toward major keywords in neuroarchitecture such as EEG, fMRI, and virtual reality.

scholarly journals Effect of Diosmin Administration in Patients with Chronic Venous Disorders on Selected Factors Affecting Angiogenesis

Molecules ◽  
2019 ◽  
Vol 24 (18) ◽  
pp. 3316 ◽  
Author(s):  
Marcin Feldo ◽  
Magdalena Wójciak-Kosior ◽  
Ireneusz Sowa ◽  
Janusz Kocki ◽  
Jacek Bogucki ◽  
...  
Keyword(s):  
Growth Factor ◽  
Clinical Symptoms ◽  
Lymphatic Drainage ◽  
Tnf Alpha ◽  
Ultrasound Images ◽  
Necrosis Factor Alpha ◽  
Factors Affecting ◽  
Wide Range ◽  
Before And After ◽  
Venous Disorders

Diosmin is a natural compound with a wide range of biological activity, e.g., it improves lymphatic drainage, supports microcirculation, and increases venous tone, and venous elasticity, hence, it is applied in the pharmacotherapy of chronic venous disorders (CVD). The aim of this study was to assess the correlation between diosmin administration (2 × 600 mg daily) in patients suffering from CVD and the levels of selected factors influencing angiogenesis, which are involved in CVD pathophysiology. Thirty-five CVD patients were examined. Levels of plasma tumor necrosis factor alpha (TNF alpha), vascular endothelial growth factor (VEGF-A and VEGF-C); angiostatin, interleukin 6 (IL-6), fibroblast growth factor 2 (FGF2); and plasminogen (PLG) were measured with an Elisa assay before and after three months of diosmin administration. The clinical symptoms of CVD were monitored using ultrasound images, echo Doppler assay, visual analogue scale (VAS), and measurement of the leg circumference. The average content of TNF alpha, VEGF-C, VEGF-A IL-6, and FGF2 decreased after the therapy with diosmin in a significant manner; with p < 0.001, p < 0.05, p < 0.05, p < 0.01, and p < 0.01, respectively, and a significant (p < 0.05) increase in the plasma angiostatin level after the three-month treatment was found. A significant (p < 0.05) decrease in edema and the average leg circumference of the patients was observed after the therapy. Diosmin influences the angiogenic and inflammatory mechanisms involved in the pathophysiology of edema presented in patients with a different class of CVD.

Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects

1990 ◽  
Vol 122 (2) ◽  
pp. 206-210 ◽  
Author(s):  
Andrea Giustina ◽  
Mauro Doga ◽  
Corrado Bodini ◽  
Angela Girelli ◽  
Fabio Legati ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Random Order ◽  
Serum Cortisol ◽  
Cortisone Acetate ◽  
Acute Administration ◽  
Acute Effects ◽  
Gh Secretion ◽  
Normal Man ◽  
The Relationship ◽  
Dose Dependent

Abstract Glucocorticoids have been shown to inhibit GH secretion in normal man when administered in large amounts for several days. The aim of our study was 1. to investigate the acute effects of a single dose of glucocorticoids on GH secretion in normal man; 2. to look at the relationship between the increase in serum cortisol concentration and GH response to the stimuli. Six healthy volunteers received on three occasions in random order an iv injection of GHRH (1–29) NH2, 100 μg, alone or 60 min after oral administration of either 25 or 50 mg of cortisone acetate. Mean stimulated GH levels, GH peak and integrated GH concentration were significantly lower after GHRH plus cortisone 25 mg than after GHRH alone. Mean GH levels at 15 and 30 min after GHRH injection and the peak GH level showed a further decrease after GHRH plus cortisone 50 mg. We conclude that acute administration of pharmacological doses of glucocorticoids is able to inhibit GH response to GHRH, probably through enhancement of endogenous somatostatin release. Moreover, this pharmacological effect of glucocorticoids seems to be dose-dependent and thus directly related to serum cortisol concentrations.

Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients

1993 ◽  
Vol 129 (5) ◽  
pp. 399-408 ◽  
Author(s):  
Torben Laursen ◽  
Jens OL Jorgensen ◽  
Hans Ørskov ◽  
Jens Møller ◽  
Alan G Harris ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Animal Studies ◽  
Area Under The Curve ◽  
Insulin Like Growth Factor ◽  
Gh Secretion ◽  
Factor I ◽  
Igf I ◽  
Growth Factor I ◽  
Igfbp 3

Animal studies have demonstrated that in addition to inhibiting growth hormone (GH) secretion octreotide inhibits in a direct manner hepatic or peripheral insulin-like growth factor I (IGF-I) generation. To test this hypothesis in humans we studied ten GH-deficient patients with frequent blood sampling during 38 h on two occasions. Regular GH therapy was discontinued 72 h prior to each study period. At the start of each study a subcutaneous (sc) injection of GH (3 IU/m2) was given (at 18.00 h). In a single-blinded crossover design, patients received a continuous sc infusion of either octerotide (200 μg/24 h) or placebo (saline). The pharmacokinetics of GH were similar on the two occasions. The area under the curve±sem of serum GH was 142.5±53.6 μg·l−1·h−1 (octreotide) and 144.8±41.8 μg·l−1·h−1 (placebo), (p=0.73); Cmax (μg/l) was 12.5±1.47 (octreotide) and 12.8±1.42 (placebo) (p=0.83), and Tmax (h) was 6.1±0.97 (octreotide) and 5.2±0.65 (placebo) (p=0.49). Growth hormone administration was associated with an increase in serum IGF-I (μg/l), which was identical during the two studies, from 85.3±19.4 to 174.25±30.3 for octreotide and from 97.0±26.4 to 158.8±28.2 for placebo. Mean IGF-I levels (μg/l) were 138.2±25.1 (octreotide) and 134.5±28.6 (placebo) (p=0.78). Similarly, the increase in IGF binding protein 3 (IGFBP-3) levels was identical. Mean IGFBP-3 levels (μg/l) were 2303±323 (octreotide) and 2200±361 (placebo) (p=0.25). Mean insulin levels were significantly lower during octreotide treatment (39.9±17.9 mU/l) than during placebo (59.7±17.8 mU/l) (p<0.05). Mean blood glucose levels were elevated significantly during octreotide infusion (5.98±0.23 mmol/l for octreotide and 5.07±0.16 mmol/l for placebo; p=0.001). Glucagon levels decreased non-significantly (p=0.07) and IGFBP-1 levels tended to increase during infusion of octreotide although not significantly (p=0.41). Levels of the lipid intermediates were identical on the two occasions. Alanine and lactate levels were significantly increased during octreotide infusion. Mean levels of blood alanine (μmol/l) were 470.8±24.2 (octreotide) and 360.1±17.8 (placebo) (p<0.02). Mean levels of blood lactate were 1038±81.0 (octreotide) and 894.4±73.8 (placebo) (p<0.04). We conclude that short-term continuous sc infusion of octreotide has no direct effect on the generation of IGF-I or the pharmacokinetics of exogenous GH in GH-deficient man.

scholarly journals Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays

2011 ◽  
Vol 57 (4) ◽  
pp. 555-559 ◽  
Author(s):  
David R Clemmons
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Normative Data ◽  
Consensus Statement ◽  
International Workshop ◽  
Research Society ◽  
Insulin Like Growth Factor ◽  
Gh Secretion ◽  
Assay Performance ◽  
Igf I

Abstract Growth hormone (GH) and insulin-like growth factor I (IGF-I) measurements are widely used in the diagnosis of disorders of GH secretion, evaluation of children with short stature from multiple causes, management of disorders that lead to nutritional insufficiency or catabolism, and monitoring both GH and IGF-I replacement therapy. Therefore, there is an ongoing need for accurate and precise measurements of these 2 peptide hormones. Representatives of the Growth Hormone Research Society, the IGF Society, and the IFCC convened an international workshop to review assay standardization, requirements for improving assay comparability, variables that affect assay interpretation, technical factors affecting assay performance, assay validation criteria, and the development and use of normative data. Special attention was given to preanalytical conditions, the use of international commutable reference standards, antibody specificity, matrix requirements, QC analysis, and interference by binding proteins. Recommendations for each of these variables were made for measurements of each peptide. Additionally, specific criteria for IGF-I were recommended for age ranges of normative data, consideration of Tanner staging, and consideration of the effect of body mass index. The consensus statement concludes that major improvements are necessary in the areas of assay performance and comparability. This group recommends that a commutable standard for each assay be implemented for worldwide use and that its recommendations be applied to accomplish the task of providing reliable and clinically useful results.

IGF-I does not affect the net increase in GH release in response to arginine

2002 ◽  
Vol 283 (4) ◽  
pp. E702-E710 ◽  
Author(s):  
Ralf Nass ◽  
Suzan S. Pezzoli ◽  
Ian M. Chapman ◽  
James Patrie ◽  
Raymond L. Hintz ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Young Adults ◽  
Growth Factor ◽  
Negative Feedback ◽  
Random Order ◽  
Feedback Effect ◽  
Insulin Like Growth Factor ◽  
Gh Secretion ◽  
Factor I ◽  
Igf I

Arginine stimulates growth hormone (GH) secretion, possibly by inhibiting hypothalamic somatostatin (SS) release. Insulin-like growth factor I (IGF-I) inhibits GH secretion via effects at the pituitary and/or hypothalamus. We hypothesized that if the dominant action of IGF-I is to suppress GH release at the level of the pituitary, then the arginine-induced net increase in GH concentration would be unaffected by an IGF-I infusion. Eight healthy young adults (3 women, 5 men) were studied on day 2 of a 47-h fast for 12 h (35th-47th h) on four occasions. Saline (Sal) or 10 μg · kg−1 · h−1recombinant human IGF-I was infused intravenously for 5 h from 37 to 42 h of the 47-h fast. Arginine (Arg) (30 g iv) or Sal was infused over 30 min during the IGF-I or Sal infusion from 40 to 40.5 h of the fast. Subjects received the following combinations of treatments in random order: 1) Sal + Sal; 2) Sal + Arg; 3) IGF-I + Sal; 4) IGF-I + Arg. Peak GH concentration on the IGF-I + Arg day was ∼45% of that on the Sal + Arg day. The effect of arginine on net GH release was calculated as [(Sal + Arg) − (Sal + Sal)] − [(IGF-I + Arg) − (IGF-I + Sal)]. There was no significant effect of IGF-I on net arginine-induced GH release over control conditions. These findings suggest that the negative feedback effect of IGF-I on GH secretion is primarily mediated at the pituitary level and/or at the hypothalamus through a mechanism different from the stimulatory effect of arginine.

scholarly journals Increased Orderliness of Growth Hormone (GH) Secretion in GH-Deficient Adults with Low Serum Insulin-Like Growth Factor I

2002 ◽  
Vol 87 (6) ◽  
pp. 2863-2869 ◽  
Author(s):  
Johan Svensson ◽  
Johannes D. Veldhuis ◽  
Ali Iranmanesh ◽  
Bengt-Åke Bengtsson ◽  
Gudmundur Johannsson
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Serum Insulin ◽  
Insulin Like Growth Factor ◽  
Gh Secretion ◽  
Factor I ◽  
Growth Factor I ◽  
Low Serum

Serum Ghrelin Concentrations are Increased in Children With Growth Hormone Insensitivity and Decrease During Long-Term Insulinlike Growth Factor-I Treatment

2008 ◽  
Vol 56 (1) ◽  
pp. 26-31 ◽  
Author(s):  
Aysin Uckun-Kitapci ◽  
Andrea M. Haqq ◽  
Jonathan Q. Purnell ◽  
Kenneth Newcomb ◽  
Hakan Gulkesen ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Normal Control ◽  
Blood Draw ◽  
Gh Secretion ◽  
Factor I ◽  
Insulinlike Growth Factor ◽  
Igf I ◽  
Growth Factor I ◽  
Insulinlike Growth Factor I

BackgroundGhrelin increases food intake, body weight, and growth hormone (GH) secretion. Serum concentrations of ghrelin are low in obese hyperinsulinemic persons, are reduced by infusion of insulin into normal-weight subjects, and are increased in underweight hypoinsulinemic patients with anorexia nervosa. Laron syndrome is an autosomal recessive disorder of GH insensitivity that results in decreased insulinlike growth factor-I (IGF-I) synthesis and growth failure. These patients have elevated GH levels, excess adipose tissue, and are insulin resistant. Because IGF-I has insulinlike actions and patients with GH insensitivity syndrome (GHIS) exhibit excess adiposity, we sought to determine whether ghrelin levels were elevated in these patients and potentially regulated by IGF-I replacement.MethodsThirteen children with GHIS and 20 normal control children matched for age, sex, and body mass index underwent complete physical examination and a fasting blood draw at baseline. The GHIS subjects then underwent follow-up fasting blood draws during therapy with human recombinant IGF-I (80-120 μg/kg, given subcutaneously twice daily). Fasting glucose, insulin, and IGF-I concentrations were measured at the time of collection. Fasting total ghrelin levels were measured on stored serum samples.ResultsThe GHIS subjects had 2-fold higher fasting ghrelin levels (2926 ± 1869 pg/mL) compared with the normal control children (1492 ± 493 pg/mL; P = 0.009), and mean ghrelin values were reduced 56% during 6.4 ± 0.2 years of IGF-I replacement (P < 0.05).ConclusionsGrowth hormone resistance and low IGF-I levels are associated with elevated ghrelin levels, which may potentiate GH secretion and adiposity in these children. Suppression of ghrelin during IGF-I treatment suggests a novel mechanism potentially regulating ghrelin levels.

Sign in / Sign up

Export Citation Format

Share Document